Abstract:<h3>Purpose/Objective(s)</h3> To retrospectively investigate the efficacy and prognostic factors of multiple/all lesions stereotactic ablative radiotherapy (SABR) for oligometastatic renal carcinoma (RCC). <h3>Materials/Methods</h3> The present study retrospectively reviewed thirty-five patients with oligometastatic RCC (1-5 metastases) who received stereotactic ablative radiotherapy (SABR) between April 2015 and December 2020. All patients were treated with SABR (6-10Gy/f, 5 or 10f) or partial-SABR boost to the lesions (40-60Gy/20-25f with tumor center boosted with 6-8Gy/f, 3-5f) for bulky tumors or tumors adjacent to critical organs. 31 patients underwent systematic therapy. Daily CBCT image guidance was used for each patient. Thirty-one patients underwent targeted therapy or targeted plus immunotherapy. <h3>Results</h3> 35 patients with 8 primary lesions and 92 metastatic lesions were included in this study. The median follow-up time was 17.0 months (range 6.1-75.4 months). The average age of all patients was 63 years. Clear cell renal cell carcinoma accounted for 77.1% of all RCC cases. Four patients (11.4%) had sarcomatoid differentiation. 78.5% of the patients had an intermediate or poor IMDC risk. Surgery on primary or metastatic sites was previously performed in 85.7% patients. The median time interval from first distant metastasis radiation therapy (DM-RT) was 7.2 months (range 0 to 50.2 months). Of the patients, 19 were treated for all primary and/or metastatic lesions. Forty percent of the patients received RT before tyrosine kinase inhibitor (TKI) failure. Of the 48 irradiated lesions, 15 received SABR, and 33 received partial-SABR. The local control rate (LRFS), progression-free survival rate (PFS) and overall survival rate (OS) of the whole group at 1 and 3 years were 78% and 78% and 41.8% and 27.9% and 78.3% and 48.2%, respectively. Univariate analysis showed that OS benefit were found in patients who received radiation before tyrosine kinase inhibitor (TKI) failure (p = 0.006) and a short time interval (<6 months) to radiotherapy (p = 0.046). Similar results were also found in PFS in patients who received radiation before TKI failure (p = 0.049) or within 8 months (p = 0.047). There were certain differences in PFS (P = 0.033) between patients receiving radiotherapy to all lesion and those to selected tumors. In multivariate analysis, OS benefits were found in patients who received SABR before TKI failure (p = 0.028). There were certain differences in PFS (P =0.033) between patients receiving radiotherapy to all lesion and those to selected tumors. In multivariate analysis, OS benefits were found in patients who received radiotherapy before TKI failure (p = 0.028), but there was no significant difference in relation to other characters due to the small sample size. <h3>Conclusion</h3> Early use of SABR and all sites irradiation may improve survival. Partial-SABR for bulky lesions close to critical organs could be safely and effectively applied under certain circumstances.

Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions

Multi-institutional analysis of extracranial oligometastatic colorectal cancer patients treated with stereotactic body radiation therapy: TROD 02-008 study

Stereotactic body radiation therapy in non-liver colorectal metastases: a scoping review

Efficacy and Safety Outcomes of Using Stereotactic Ablative Radiotherapy for Oligometastatic Lesions from Colorectal Cancer

Stereotactic radiotherapy for liver oligometastases: a pooled analysis following the estro/eortc consensus recommendations

Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes

[Stereotactic body radiation therapy for patients with lung and liver oligometastases from colorectal cancer: a phase Ⅱ trial].

Stereotactic body radiation therapy (SBRT) for patients with oligometastatic/oligoprogressive adrenal metastases: Outcomes and toxicities profile in a monoinstitutional study.

Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer

Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study

Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients with Lung Oligometastases or Oligoprogression from Colorectal Cancer

Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients

Stereotactic Radiation Therapy (SRT) for Brain Metastases of Multiple Primary Tumors: A Single Institution Retrospective Analysis.

Stereotactic body radiotherapy as a viable treatment on extracranial oligometastases in melanoma patients: a retrospective multicentric study

Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis

Long-Term Results of Stereotactic Radiotherapy in Patients with at Least 10 Brain Metastases at Diagnosis

Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer with Oligometastases, Oligoprogression, or Local Control of Dominant Tumors

Outcomes of Multiple/All lesions Stereotactic Ablative Radiation Therapy (SABR) for Oligo-Metastatic Renal Cancer

Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer

Stereotactic radiotherapy for pulmonary oligometastases: a systematic review

Stereotactic radiotherapy for brain oligometastases